Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
PAVmed Inc. is a highly differentiated, multiproduct medical device company employ...
PAVmed Inc. is a highly differentiated, multipr...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...
Arrowhead Pharmaceuticals develops medicines th...
At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...
At PRA Health Sciences, we work side-by-side wi...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Akero aims to develop and deliver transformational medicines to patients with high...
Akero aims to develop and deliver transformatio...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.